Loading
Liver Disease Diagnosis and Treatment · Journal article
Scientific Reports · September 2, 2026
Reinforces what was already believed, rather than introducing something new.
This observational cohort study from the UK Biobank found no significant association between aspirin use and MAFLD over a median 9.41-year follow-up after propensity score matching and adjustment for metabolic confounders. Exploratory stratified analyses suggested a possible protective effect in participants with obesity (OR 0.69) and an interaction with stroke history, but the authors explicitly label these findings as hypothesis-generating due to multiple comparisons and small subgroup numbers.
Observational cohort study with propensity score matching. UK Biobank participants; selection criteria and exact eligibility not fully specified in source; included measurements of age, gender, BMI, lifestyle factors, metabolic and liver function indicators.. Intervention: Aspirin use (specific dose, frequency, and duration not stated in source). Compared with: No aspirin use. n = 3,922. UK Biobank (UK-based registry).
Aspirin use not significantly associated with MAFLD overall: OR = 0.97, 95% CI 0.82–1.15, consistent across sensitivity analyses Among participants with obesity (BMI ≥ 30 kg/m²), aspirin associated with lower MAFLD: OR 0.69, 95% CI 0.52–0.92 No associations found in normal-weight or overweight groups
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should not expect aspirin to prevent or treat MAFLD based on this evidence. The exploratory finding of benefit in obesity is preliminary and requires confirmation in adequately powered prospective studies; the stroke interaction is too underpowered to guide clinical practice.
Observational cohort study with propensity score matching showing no primary association between aspirin and MAFLD, with exploratory subgroup findings that the authors themselves characterize as hypothesis-generating due to multiple comparisons.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should not expect aspirin to prevent or treat MAFLD based on this evidence. The exploratory finding of benefit in obesity is preliminary and requires confirmation in adequately powered prospective studies; the stroke interaction is too underpowered to guide clinical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This study investigated the association between aspirin use and metabolic dysfunction-associated fatty liver disease (MAFLD). Based on data from the UK Biobank (UKB), this study included a variety of covariates such as age, gender, BMI, lifestyle factors, metabolic indicators and liver function indicators, and assessed the association between aspirin use and MAFLD after balancing the baseline differences by the propensity score matching (PSM) method, and explored the influencing factors by stratified analyses and interaction tests. During a median follow-up period of 9.41 years, among 3,922 participants, aspirin use was not significantly associated with MAFLD after adjusting for a variety of metabolic confounders (OR = 0.97, 95% CI: 0.82–1.15), a finding that was consistent across sensitivity analyses. When BMI was modeled categorically, a significant association was observed only among participants with obesity (BMI ≥ 30 kg/m²; OR 0.69, 95% CI 0.52–0.92), whereas no associations were found in normal-weight or overweight groups. An exploratory interaction was observed between aspirin use and stroke history (aspirin × stroke, OR for interaction = 0.07, 95% CI: 0.008–0.646, P = 0.019). In this observational study, aspirin use was not significantly associated with MAFLD. Exploratory analyses suggested possible heterogeneity according to BMI and stroke history; however, these findings should be considered hypothesis-generating because of multiple comparisons and the small number of participants with a history of stroke. Overall, aspirin use was not significantly associated with MAFLD.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.